# A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

> **NCT03521154** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 216 (actual)

## Conditions studied

- Non Small Cell Lung Cancer (Stage III)

## Interventions

- **DRUG:** Osimertinib 80mg/40mg
- **DRUG:** Placebo Osimertinib 80mg/40mg

## Key facts

- **NCT ID:** NCT03521154
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-07-19
- **Primary completion:** 2024-01-05
- **Final completion:** 2027-10-29
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03521154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03521154, "A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03521154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*